Form 4: Neogenomics CFO Jeffrey Scott Sherman Reports Stock Option and Unit Grants
SEC Form 4 Filing
Chief Financial Officer Jeffrey Scott Sherman reports the acquisition of stock options, restricted stock units, and performance stock units in Neogenomics Inc.
Summary
- Jeffrey Scott Sherman, CFO of Neogenomics Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report includes the grant of stock options, restricted stock units (RSUs), and performance stock units (PSUs).
- Sherman directly owns 125,662 shares of common stock.
- He holds options to buy 249,169 shares at $11.62, vesting over four years from December 2022.
- He holds options to buy 73,016 shares at $19.65, vesting over three years from May 2023.
- He holds 39,016 RSUs granted in May 2023, vesting over three years.
- He holds 39,016 PSUs granted in May 2023, with a maximum of 58,524 shares possible based on performance.
- On February 23, 2024, Sherman was granted 77,913 stock options at $16.45, vesting over three years.
- On February 23, 2024, Sherman was granted 46,606 RSUs, vesting over three years.
- On February 23, 2024, Sherman was granted 46,606 PSUs, with a maximum of 69,910 shares possible based on performance.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future performance. The grants are performance-based, which is a positive signal.
Positives
- The grant of stock options and units aligns the CFO's interests with those of the shareholders, incentivizing performance and company growth.
Future Outlook
The vesting of stock options and units is contingent upon continued service with the company and, in the case of performance stock units, the achievement of certain share and revenue growth goals.
Industry Context
Stock option and unit grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Equity compensation practices vary across the biotechnology industry, but grants to CFOs typically include a mix of stock options, restricted stock units, and performance-based units.
- Comparable companies like Exact Sciences and Guardant Health also utilize similar equity compensation structures for their executive teams.
- The specific number of shares and vesting schedules are tailored to the individual's role, performance, and the company's overall compensation strategy.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
- The grants have no immediate impact on customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/05/2022 | Mr. Sherman was granted 249,169 stock options. |
| 12/07/2023 | First tranche of stock options granted on December 5, 2022, vests. |
| 05/11/2023 | Mr. Sherman was granted 73,016 stock options, 39,016 restricted stock units, and 39,016 performance stock units. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2024 | Mr. Sherman was granted 77,913 stock options, 46,606 restricted stock units, and 46,606 performance stock units. |
| 02/23/2027 | Expiration date for performance stock units granted on February 23, 2024. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.